Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time
Author(s): Heustess Allie, Spigener Shuler, Sweitzer Sarah, Romero-Sandoval Alfonso, Asbill Scott
Issue: Mar/Apr 2015 - Volume 19, Number 2
View All Articles in Issue
Page(s): 167-173
Download in electronic PDF format for $75
Abstract: Many patients with chronic neuropathic pain continue to suffer despite traditional pharmacotherapy. As a result, pharmacists commonly compound gabapentin into creams, gels, and ointments as an alternative treatment option. In this study, various concentrations (1%, 5%, and 10%) of topical gabapentin compounded in Lipoderm were applied at various pre-treatment times (30 minutes, 1 hour, and 4 hours) to investigate what gabapentin concentration and pre-treatment time best attenuates formalin-induced nociceptive behaviors in a rodent model. A 30-minute pre-treatment with 5% gabapentin demonstrated maximum attenuation of nociceptive behaviors in this in vivo preclinical pain model. Nociceptive behaviors unexpectedly increased when gabapentin concentration or pre-treatment time was increased, suggesting both antinociceptive and pronociceptive effects of transdermal gabapentin administration. Gabapentin permeation into the skin and deeper tissues of the hindpaw was measured following the in vivo study. Skin and deep tissue permeation of gabapentin was both dose and time-dependent. Maximum deep tissue permeation occurred within 30 minutes of topical application. Skin concentrations increased with a longer 1-hour pre-treatment. Minimal skin and deeper tissue levels were found following a 4-hour pre-treatment. These results suggest that topical gabapentin may be antinociceptive in a rodent formalin model at specific doses and pre-treatment intervals.
Related Keywords:
gabapentin, chronic pain, neuropathic pain, neuropathy, topical analgesics, topical preparation, transdermal delivery, skin permeation, transdermal penetration, formalin pain model, dose-dependent pain relief, analgesia, voltage-dependent calcium channel blocker, alpha-2-delta subunit inhibitor, pain-related behavior, antinociception
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time
Heustess Allie, Spigener Shuler, Sweitzer Sarah, Romero-Sandoval Alfonso, Asbill Scott
|
Mar/Apr 2015
Pg. 167-173
|
Veterinary Transdermal Medications: A to Z
Davidson Gigi S
|
Mar/Apr 2003
Pg. 106-113
|
Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy?
Shakshuki Ayah, Agu Remigius U
|
Nov/Dec 2019
Pg. 496-503
|
Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
|
May/Jun 2010
Pg. 182-192
|
Skin Penetration and Antinociception of Topical Gabapentin Formulations
Bryson Evan, Asbill Scott, Sweitzer Sarah
|
Nov/Dec 2014
Pg. 504-511
|
Skin Permeation and Antinociception of Compounded Topical Cyclobenzaprine Hydrochloride Formulations
Bryson Evan, Hartman Rachel, Arnold John, Gorman Greg, Sweitzer Sarah.Asbill Scott
|
Mar/Apr 2015
Pg. 161-166
|
Topical Medications for Orofacial Neuropathic Pain
Bramwell Bethany L
|
May/Jun 2010
Pg. 200-203
|
Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model
Baneshi Marzieh, Tyagi Deependra, Panneerselvam Ezilrani, MacKenzie Graham, Coleman Johngary, Zhang Shine X
|
Sep/Oct 2023
Pg. 424-430
|
Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin
Le Uyen Minh, Baltzley Sarah, AlGhananeem Abeer
|
Nov/Dec 2018
Pg. 498-503
|
Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
|
Mar/Apr 2024
Pg. 111-116
|
Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
|
Jul/Aug 2015
Pg. 295-300
|
Effect of Penetration Enhancers on the Percutaneous Delivery of Pain Management Actives
Trimble John, Light Bob
|
May/Jun 2016
Pg. 250-256
|
Topical Treatment of Neuropathic Pain
Vadaurri Vince
|
May/Jun 2008
Pg. 182-190
|
Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
|
Jul/Aug 2004
Pg. 269-274
|
In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations
Heustess Allie, Asbill Scott, Eagerton David, Arnold John
|
Nov/Dec 2014
Pg. 512-515
|
NASEM Report on Compounded Topical Pain Creams
Allen Loyd V Jr
|
Nov/Dec 2020
Pg. 446-448
|
Amitriptyline Hydrochloride 2%, Carbamazepine 2%, Gabapentin 10%, and Ketoprofen 2% Transdermal Gel
Allen Loyd V Jr
|
Mar/Apr 2024
Pg. 131
|
Amitriptyline Hydrochloride 2%, Carbamazepine 2%, Gabapentin 10%, and Ketoprofen 2% Transdermal Gel
Allen Loyd V Jr
|
Mar/Apr 2011
Pg. 157
|
Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
|
Jan/Feb 2022
Pg. 65-71
|
Transdermal Gel in the Treatment of Postoperative Pain
Alexander Kayla, Wynn Tom
|
May/Jun 2007
Pg. 181-184
|
Return to Top |